Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:category |
endocannabinoid system modulator
|
| gptkbp:effect |
increase endocannabinoid levels
|
| gptkbp:effectOnEnzyme |
decrease MAGL activity
|
| gptkbp:effectOnNeurotransmitters |
decrease arachidonic acid
increase 2-AG |
| gptkbp:example |
gptkb:JZL184
gptkb:KML29 gptkb:URB602 ABX-1431 |
| https://www.w3.org/2000/01/rdf-schema#label |
MAGL inhibitors
|
| gptkbp:investigatedBy |
gptkb:cancer
addiction anxiety neurodegenerative diseases |
| gptkbp:mechanismOfAction |
inhibit breakdown of 2-arachidonoylglycerol
|
| gptkbp:routeOfAdministration |
oral
intravenous intraperitoneal |
| gptkbp:sideEffect |
tolerance
dependence cannabinoid-like behavioral effects |
| gptkbp:target |
gptkb:monoacylglycerol_lipase
|
| gptkbp:usedFor |
pain management
neuroinflammation cannabinoid signaling modulation |
| gptkbp:bfsParent |
gptkb:CB1_receptor_(indirect)
|
| gptkbp:bfsLayer |
6
|